List of Vyzulta drug patents
Vyzulta is owned by Bausch And Lomb.
Vyzulta contains Latanoprostene Bunod.
Vyzulta has a total of 4 drug patents out of which 0 drug patents have expired.
Vyzulta was authorised for market use on 02 November, 2017.
Vyzulta is available in solution/drops;ophthalmic dosage forms.
Vyzulta can be used as reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension.
The generics of Vyzulta are possible to be released after 03 October, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 11 months from now) | |
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 11 months from now) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 11 months from now) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic